Limited infection upon human exposure to a recombinant raccoon pox vaccine vector

Vaccine. 2004 Jul 29;22(21-22):2757-60. doi: 10.1016/j.vaccine.2004.01.030.

Abstract

A laboratory accident resulted in human exposure to a recombinant raccoon poxvirus (RCN) developed as a vaccine vector for antigens of Yersinia pestis for protection of wild rodents (and other animals) against plague. Within 9 days, the patient developed a small blister that healed within 4 weeks. Raccoon poxvirus was cultured from the lesion, and the patient developed antibody to plague antigen (F1) and RCN. This is the first documented case of human exposure to RCN.

Publication types

  • Case Reports
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Accidents, Occupational
  • Adult
  • Animals
  • Antibodies, Viral / analysis
  • Antibodies, Viral / biosynthesis
  • Female
  • Genetic Vectors
  • Humans
  • Laboratories
  • Mice
  • Plague / immunology
  • Poxviridae / immunology*
  • Poxviridae Infections / immunology*
  • Raccoons
  • Reverse Transcriptase Polymerase Chain Reaction
  • Vaccines, DNA / immunology
  • Vaccines, Synthetic / immunology
  • Viral Vaccines / immunology*
  • Yersinia pestis / immunology

Substances

  • Antibodies, Viral
  • Vaccines, DNA
  • Vaccines, Synthetic
  • Viral Vaccines